KKR IUH LLC

● 近日，楷拓生物（CATUG Biotechnology）宣布完成近亿元新一轮融资。本轮融资由倚锋资本、知壹投资领投，元禾控股、苏州园区科创基金跟投。 ● 楷拓生物成立于2021年，从成立伊始就立足先进疗法领域，聚焦创新型核酸药物CRDMO服务，在疫情叠加行业周期的复杂市场环境下，得到多方投资者的大力支持，在近三年的时间内迅速位列核酸疗法领域CDMO第一梯队。本轮资金将用于楷拓生物海外业务和全流程CRDMO服务能力升级，夯实公司在核酸药物技术赛道上的核心竞争力。 楷拓生物联合创始人、CEO王潇博士表示，感恩新老股东与合作伙伴对楷拓生物的支持与认可，让我们在周期中坚定信心、稳中求胜、砥砺前行。此次融资将进一步夯实楷拓生物在核酸药物赛道的技术先发优势，为布局海外业务、打造先进疗法各领域的定制化服务提供持续动力，楷拓将以DNA、RNA技术的创新应用能力，在传染病疫苗、通用/个性化肿瘤疫苗、基因治疗、基因编辑、体内外细胞治疗、动物疫苗等前沿领域，持续赋能客户及产业，赋技术予生命，以新质生产力加速创新疗法惠及广大病患。 倚锋资本CEO朱湃先生表示，我们非常看好楷拓生物在创新疗法研发生产服务领域的技术实力与增长潜力，尤其是公司在质粒-mRNA-LNP-F&F全流程GMP生成领域的领先地位。随着商业核酸疫苗及药物临床应用的成功，核酸技术已被充分验证其优势和潜力，未来市场规模有望实现爆发式增长。楷拓生物在这一前沿领域的技术储备和项目经验将为其带来长期发展红利，赋能创新药物更快上市，满足未被满足的治疗需求。 知壹投资创始人、CEO赵福先生表示：作为楷拓生物的老股东，知壹投资将持续陪伴并赋能楷拓生物在CGT（mRNA, Cell and Gene Therapy）领域核酸药物CRDMO的国际赛道上越做越强。楷拓生物致力于成为全球基因细胞治疗药物与核酸药物先进疗法全产业链的一站式服务平台，从成立起，其工艺技术和质量体系就定位在全球市场，目前楷拓生物的技术实力被国际业界广泛视为在核酸药物制备领域的“黑马”。我们坚信，楷拓生物将进一步巩固其在CRDMO行业的领先地位并成长为行业龙头企业，在蓬勃发展的核酸医药浪潮中扮演更加重要的角色，以技术创新造福全球患者。 - 关于楷拓生物 - 楷拓生物是一家聚焦生物医药新技术开发和应用的创新科技公司，矢志为全球核酸疗法与基因治疗提供从药物研发、质量研究、临床应用到产业化的全产业链一站式CRDMO服务。公司在中国、美国和瑞士等地设有运营基地，在苏州、武汉设有研发中心和GMP产业化基地。楷拓生物核心团队均来自于国际和国内顶尖生物科技公司与国内外知名院校和科研机构，在基因治疗与核酸治疗领域拥有丰富的产业技术与管理经验。公司以高质量大规模质粒工艺开发与生产、mRNA合成及递送全流程工艺开发与生产、核酸分析方法与质量研究四大核心技术服务平台为起点，立志打造顶尖工艺技术平台，成为新一代创新生物科技行业之楷范。 - 关于倚锋资本 - 倚锋资本是国内最早的一批生物医药专业投资机构，投资团队由一批来自国内外顶尖院校的生物医药专业博士组成，专注于全球生物医药VC/PE投资，深度筛选并投资了微芯生物、前沿生物、亚盛医药、普门科技、和铂医药、和元生物、亚虹医药、思路迪医药、真实生物、Apexigen、Centrexion和Elicio等境内外优质企业。凭借出色的投资业绩和卓越的投研实力，倚锋资本屡获业界殊荣，多次揽获包括清科·年度中国医疗健康领域投资机构30强、清科·中国创业投资机构100强、投中榜·年度最佳退出案例TOP10、投中榜·年度最佳生物医药投资机构TOP10、投中榜·年度粤港澳大湾区最佳创业投资机构TOP30、母基金·年度最佳医疗健康领域投资机构TOP30、中国最具活力的药物创新投资机构等荣誉，连续多年被评为“深圳市十佳创投机构”，曾受到世界顶级期刊《Nature》专访。倚锋旨在以资本推动生物科技成果产业化。经过数年的积累，倚锋形成“以创业者为中心，以价值创造者为本”的理念，打造出一支经验丰富、特色鲜明的专业化投资团队，并坚持投资、融资、风控、管理、服务 “五位一体”系统化运营，致力于成为以人为本、值得信赖、基业长青的卓越投资机构。 - 关于知壹投资 - 知壹投资（InnoVision Capital）是由全球最大私募股权投资机构KKR前亚洲区核心高管于2016年创建的亚洲新生代PE代表机构，团队拥有21年国际顶级机构成功的并购及投资经验，秉承国际一流的投资与风控理念，深耕亚洲及中国具有巨大发展潜力的ESG及并购投资领域。知壹投资总管理规模近200亿人民币，目前已管理三支人民币综合性PE基金及一支美元PE基金。作为亚洲新生代PE代表机构，知壹投资结合一流国际视野与深厚产业资源，深度挖掘ESG、绿色经济时代绿色低碳、可持续发展（生命科学/粮食安全）及人工智能在相关领域应用的并购及投资机会，专注于具有全球竞争力及巨大增长潜力的产业龙头。目前，知壹投资的已投企业包括众多拥有全球领先技术、强大产品能力、国内及国际领先市场地位的领军企业。自成立以来，知壹投资已成功投资了贝壳集团、京东物流、中信建投、药明康德、快手、汇川技术、万华化学、绿控传动、奕斯伟计算、58集团、青牛软件、红云融通、纽福斯、艾凯生物、楷拓生物、柯渡医学、天鹅到家等各领域龙头企业。知壹投资团队历史上在绿色经济及其他领域领导过众多成功投资及并购项目，包括联合环境（后成功被中信集团收购）、蒙牛乳业、现代牧业、远东宏信、平安保险、百丽国际、中金公司、金盘科技、软通动力、中粮家佳康等。 - 关于元禾控股 - 元禾控股自2001年成立起专注于股权投资领域，管理基金规模超千亿元，是国内领先的股权投资机构之一。自成立起，重点关注集成电路、生物医药、人工智能、纳米技术应用、云计算、大数据等新兴产业投资机会，坚持扶持实体产业，促进产业转型升级。目前，直接投资项目超1400家次，元禾母基金投资子基金174只。 - 关于苏州园区科创基金 - 苏州工业园区科创基金由苏州工业园区财审局作为LP、领军创投作为GP共同设立。基金一期总规模15亿元，聚焦生物医药、纳米技术应用、人工智能等战略性新兴产业重点领域，采取直投和拨投结合方式，支持区内科技型、创新型企业做大做优做强。苏州工业园区科创基金GP领军创投成立于2012年12月，由苏州工业园区企业发展服务中心全资控股，是目前苏州工业园区规模最大的政策性天使投资机构，在配合园区引进高端人才、促进企业快速成长、营造科技创新生态等方面发挥了积极的作用。 联系方式 企业邮箱：info@catugbio.com 商务邮箱（中国）：yuhua.liu@catugbio.com 商务邮箱（海外）：info@catug.bio 共建Biomedical创新生态圈！ 如何加入BiG会员？

According to people familiar with the matter, private equity manager Clayton Dubilier & Rice (CD&R) is emerging as the frontrunner to acquire Stada Arzneimittel, Bloomberg reported Tuesday.The sources suggest that Bain Capital and Cinven, the German generic drugmaker's private equity owners, aim to secure a valuation of around €11 billion ($11.8 billion) or more in a full sale of the business, although it remains unclear whether they will succeed. They are expected to receive bids from potential buyers this week. Aside from CD&R, sources mentioned that KKR & Co. and CVC Capital Partners have also shown interest in Stada, according to the Bloomberg report.Bain and Cinven, which took over Stada in 2017 in a deal worth €5.3 billion ($5.7 billion), are reportedly considering a potential stock market listing of Stada should bids not meet their valuation expectations. The buyout firms have been exploring a possible minority stake sale as well.A report last August said that Bain and Cinven were weighing alternatives including an outright sale that could value Stada at over €10 billion ($10.7 billion), or an IPO. At the time, Stada CEO Peter Goldschmidt confirmed the owners were in an "orientation phase" of exploring options, but downplayed any pressure for an imminent deal.This past April, sources said that Stada's management had kicked off talks with potential buyers including private equity firms like CD&R, CVC and KKR as well as pension funds and other entities. The sale target was said to be around €8 billion ($8.6 billion).

The company aims to develop new antibody-drug conjugates for cancer treatment. Credit: Max Acronym / Shutterstock. France-based biopharmaceutical company Adcytherix has announced its launch with seed funding of €30m ($32.2m) aimed at developing new antibody-drug conjugates (ADCs) for cancer treatment. Recommended Buyer's Guides Buyer's Guide Leading Guide to Compliance Software for the Pharmaceutical Industry Buyer's Guide Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry The company will focus on the development of ADCs targeting diseases with significant unmet medical needs. The financial injection marks a significant milestone for Adcytherix, which was founded by Jack Elands and Pontifax Venture Capital. Xavier Preville and Carsten Dehning are co-founders. Jack Elands is CEO, Dehning is chief financial officer and Preville is research and preclinical development vice-president and head. The seed funding round was spearheaded by Pontifax and received support from a consortium of top-tier life science investors, including RA Capital Management, Pureos Bioventures and Dawn Biopharma — a platform under the control of global investment firm KKR . See Also: Takeda signs option agreement with Ascentage for CML drug UK’s new Netflix-style funding model for antibiotics goes live The company’s management team also contributed to the seed funding. Elands stated: “Our new company has as its objective to meet the most urgent need of patients by developing a next generation of ADCs. We are excited that the top tier investors and business partners that supported us before joined us again to help us achieve our goals.” Adcytherix also welcomed new members to its supervisory committee: Ran Nussbaum and Ohad Hammer from Pontifax, Iyona Rajkomar of Dawn Biopharma, Ximing Ding of Pureos Bioventures and Matthew Hammond of RA Capital Management. Nussbaum stated: “We are excited to be part of this new adventure with a superb leadership that worked with us before. “ADCs will play a major role in the future of oncology. The team that is leading the company and the syndicate that will support Adcytherix aim to build a well-differentiated franchise in the field.” The Adcytherix founding team previously established and sold Emergence Therapeutics to Eli Lilly and Company.